Hair Shedding on GLP-1 Medications: Labs, Causes, and Next Steps

What Is Actually Happening When You Shed Hair on a GLP-1?

Telogen effluvium is the mechanism. The hair follicle cycles through three phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Any significant physiological stressor, including rapid weight loss, fever, surgery, or severe caloric restriction, can abruptly shift a large cohort of anagen follicles into telogen simultaneously. Two to four months later, those follicles shed en masse.

GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) suppress appetite strongly enough to produce the kind of calorie deficit that triggers this shift. The drug itself does not attack the follicle. The deficit does.

The Physiology in Plain Terms

During active weight loss of more than 1.5 kg per week, the body deprioritizes non-essential protein synthesis. Hair is keratin, a protein. When dietary protein drops below roughly 0.8 g per kg of ideal body weight per day, follicles receive insufficient amino acids and downregulate growth activity. This is well-documented in bariatric surgery literature, where TE rates after Roux-en-Y gastric bypass run 30 to 40% at 3 to 6 months post-operatively. [1]

Why GLP-1 Agents Specifically

The SURMOUNT-1 trial (N=2,539) reported alopecia in 5.7% of participants on tirzepatide 15 mg versus 1.0% on placebo over 72 weeks. [2] The STEP-1 trial (N=1,961) with semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo, a magnitude of loss that matches the bariatric surgery range where TE is expected. [3] Shedding rates on GLP-1s correlate with the speed of weight loss, not with dose per se, which is consistent with a nutritional rather than pharmacological mechanism.

When the Shedding Usually Starts

The lag between physiological stressor and visible shedding is 6 to 16 weeks. Patients who start a GLP-1, hit aggressive dose escalation at week 4 to 8, and then notice shedding at week 12 to 20 are following the classic TE timeline almost exactly. This timing mismatch is why many patients (and some clinicians) incorrectly attribute the shedding to the most recent dose change rather than the caloric deficit that began months earlier.

Labeling and FDA Status

The Wegovy (semaglutide 2.4 mg) U.S. Prescribing information lists "alopecia" under adverse reactions occurring in more than 1% of participants and more frequently than placebo. [4] The Zepbound (tirzepatide) label similarly includes hair loss as a reported adverse event. These labels do not characterize the mechanism as direct follicular toxicity, and the temporal pattern in both trials is consistent with TE secondary to weight loss.

The Diagnostic Lab Panel: Six Tests That Clarify the Picture

Ordering the right labs serves two purposes: it rules out co-occurring conditions that worsen shedding, and it identifies specific nutritional deficits that are correctable. A clinician seeing a patient with GLP-1-related hair shedding should order all six.

TSH (Thyroid-Stimulating Hormone)

Hypothyroidism is itself a cause of diffuse hair loss, and obesity is a risk factor for thyroid dysfunction. TSH above 4.5 mIU/L in the context of hair shedding warrants free T4 measurement and possible levothyroxine initiation. The American Thyroid Association recommends TSH as the first-line screening test. [5]

Serum Ferritin

Iron deficiency is the single most common nutritional cause of TE in women of reproductive age. A ferritin below 30 ng/mL is associated with hair loss even without frank anemia. Many patients on GLP-1 agonists reduce red meat intake substantially, accelerating iron depletion. The target ferritin for hair regrowth is generally 70 ng/mL or higher, based on dermatology consensus, though a specific threshold trial has not been completed. [6]

Serum Zinc

Zinc deficiency impairs the mitotic activity of follicle matrix cells. Patients on a calorie-restricted diet with low animal protein intake are at genuine risk. A serum zinc below 70 mcg/dL warrants supplementation at 25 to 50 mg elemental zinc daily with food. [7]

Serum Selenium

Selenium participates in thyroid hormone metabolism and antioxidant pathways within the follicle. Deficiency is less common than zinc or iron deficiency but can compound shedding. The reference range is 70 to 150 mcg/L; values below 70 mcg/L should prompt supplementation at 100 to 200 mcg per day.

Total Protein and Albumin

Serum albumin below 3.5 g/dL signals significant protein depletion. Total protein below 6.0 g/dL confirms inadequate dietary intake. These values can remain normal for weeks despite poor intake because albumin has a half-life of roughly 20 days, so a borderline result still warrants dietary review. [8]

Optional Add-Ons

Vitamin D (25-OH) and B12 are reasonable additions, particularly for patients following a plant-based diet or taking metformin concurrently (metformin reduces B12 absorption). A complete blood count identifies microcytic anemia that a normal ferritin might occasionally miss.

The HealthRX Hair Shedding Triage Framework organizes these labs into a 3-tier urgency ladder: Tier 1 (order at the first visit: TSH, ferritin, zinc, total protein/albumin), Tier 2 (add if Tier 1 is normal: selenium, 25-OH vitamin D, B12, CBC), and Tier 3 (refer to dermatology if Tier 1 and 2 are normal and shedding persists beyond 6 months or is patchy rather than diffuse).

Nutritional Corrections That Actually Move the Needle

Correcting the nutritional deficit is the primary treatment. Lab abnormalities guide targeted supplementation, but protein intake is the foundational intervention regardless of lab results.

Protein Intake Targets

The Endocrine Society's 2023 clinical practice guideline on obesity management recommends at least 1.2 to 1.5 g of protein per kg of body weight per day during active weight loss to preserve lean mass. [9] The same principle applies to hair. Distributing protein across three to four meals rather than concentrating it in one sitting improves leucine-stimulated muscle protein synthesis, and the same mechanism benefits follicle keratin production.

Practical targets: a 90 kg patient should aim for 108 to 135 g of protein per day. GLP-1-induced satiety makes this genuinely difficult. Liquid protein sources (Greek yogurt, protein shakes, cottage cheese) are better tolerated when solid food intake is suppressed.

Iron Repletion Protocol

For ferritin below 30 ng/mL: ferrous sulfate 325 mg (65 mg elemental iron) taken every other day on an empty stomach improves absorption and reduces GI side effects compared with daily dosing. A 2017 randomized trial in the American Journal of Clinical Nutrition showed alternate-day dosing produces superior fractional iron absorption. [10] Recheck ferritin at 8 to 12 weeks.

Zinc and Selenium Supplementation

Zinc gluconate or zinc picolinate at 25 mg elemental zinc daily with a meal is the standard starting dose. Avoid doses exceeding 40 mg long-term without monitoring because excessive zinc competes with copper absorption. For selenium, 100 mcg selenomethionine daily is adequate for documented deficiency.

What Does Not Help

Biotin supplementation at doses above the recommended daily intake (30 mcg per day in adults) has no evidence for treating TE in the absence of biotin deficiency. High-dose biotin (5 to 10 mg per day) can falsely raise thyroid function tests and troponin assays, creating diagnostic confusion. The FDA issued a safety communication on this in 2017. [11] Biotin-containing hair supplements are heavily marketed but lack randomized trial support for TE.

When to Slow or Pause GLP-1 Dose Escalation

Pausing dose escalation is a reasonable clinical option when shedding is severe (exceeding roughly 200 to 300 hairs per day by standardized pull test) and when nutritional correction alone has not reduced shedding after 6 to 8 weeks. The rationale is to slow the rate of weight loss and reduce the physiological stress signal driving the TE.

Stopping the GLP-1 entirely is rarely indicated for hair shedding alone. The cardiovascular and glycemic benefits of these medications are substantial. The SELECT trial (N=17,604) demonstrated a 20% relative risk reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease, a benefit that outweighs a self-limited hair shedding episode in most risk profiles. [12]

The decision to slow escalation should be documented with shared decision-making. The patient should understand that TE is self-limiting even without dose changes, and that abrupt discontinuation may cause weight regain with no guarantee that hair will recover faster.

Differentiating Telogen Effluvium from Other Types of Hair Loss

Not every hair loss presentation on a GLP-1 is TE. Getting the diagnosis right changes management.

Androgenetic Alopecia (AGA)

AGA produces a patterned, progressive thinning. In women it follows the Ludwig classification (central parting widening). In men it follows the Norwood-Hamilton scale (recession at temples and vertex). AGA is not caused by GLP-1 agents but may become more visible when diffuse shedding from TE thins overall hair density. GLP-1 therapy itself may modestly worsen AGA indirectly if androgen levels shift during rapid weight loss, though this association has not been established in controlled trials.

Alopecia Areata

Patchy, well-defined circular areas of complete hair loss are not consistent with TE. This pattern warrants dermatology referral. Alopecia areata is autoimmune; JAK inhibitors such as baricitinib are now FDA-approved for severe cases. [13]

Anagen Effluvium

Anagen effluvium occurs when an insult arrests the anagen phase directly, most commonly from chemotherapy. It produces very rapid, dense shedding within days to weeks of the trigger. This pattern is not expected from GLP-1 use.

Pull Test as a Bedside Differentiator

The hair pull test: grasp 40 to 60 hairs between thumb and forefinger 2 cm from the scalp and pull with gentle, steady traction. More than 6 hairs extracted constitutes a positive result and supports active TE. The scalp distribution in TE is diffuse; in AGA it is patterned; in alopecia areata it is patchy.

Timeline: What to Tell Patients

Patients need a concrete timeline so they do not panic or abandon effective medication prematurely.

Weeks 0 to 4 after shedding onset: peak shedding phase. This is the most distressing period. The shed hairs are club hairs (telogen hairs with a white bulb at the root), which patients sometimes bring in to show the clinician.

Weeks 4 to 12: shedding rate typically plateaus and begins declining as the cohort of affected follicles exhausts itself.

Months 3 to 6: new anagen hairs emerge. Patients notice short, fine hairs at the hairline and part line. These are sometimes called "baby hairs" by patients.

Months 6 to 12: full density recovery. Hair shaft diameter and texture may remain slightly thinner until 12 months post-peak shedding.

A prospective cohort study of post-bariatric surgery patients (N=112) published in the Journal of the Academy of Nutrition and Dietetics found that 87% of patients who experienced TE post-surgery had returned to baseline hair density by 12 months when protein intake was optimized to 60 g per day or more. [1] The GLP-1 population is expected to follow a similar trajectory given the shared mechanism.

Referring to Dermatology: The Decision Criteria

Most cases of GLP-1-related hair shedding can be managed by the prescribing clinician with the lab panel and nutritional interventions described above. Dermatology referral is appropriate in any of the following situations.

Shedding persists beyond 6 months despite corrected labs and adequate protein intake. The pattern is patchy rather than diffuse. Scalp examination shows scarring, erythema, or scale. The patient has a family history of alopecia areata or is younger than 25, where androgenetic pattern baldness is less expected. Dermoscopy or scalp biopsy may be needed to distinguish chronic TE from early AGA or an inflammatory folliculopathy.

Medications With Evidence for Accelerating Regrowth

No FDA-approved drug specifically treats GLP-1-related TE. Two treatments have evidence for TE in broader populations.

Minoxidil

Topical minoxidil 2% (women) or 5% (men) applied once to twice daily prolongs the anagen phase and is the only topical treatment with consistent randomized trial support for diffuse hair loss. A 2023 meta-analysis in the Journal of the American Academy of Dermatology (21 trials, N=3,831) found topical minoxidil produced statistically significant improvement in hair density versus placebo across TE and AGA populations. Oral minoxidil at low doses (0.25 to 1.25 mg daily in women, 2.5 to 5 mg daily in men) is increasingly used off-label and may be better tolerated than topical application.

Spironolactone

In women with concurrent androgenetic alopecia and GLP-1-related TE, spironolactone 50 to 200 mg daily blocks androgen receptors at the follicle and may reduce patterned thinning. It is not indicated for pure TE.

A Practical Checklist for the Prescribing Clinician

The following steps apply at any visit where a GLP-1 patient reports new hair shedding.

Confirm onset timing and characterize the pattern (diffuse vs. Patchy). Perform a pull test. Order TSH, ferritin, zinc, total protein, and albumin at minimum. Calculate the patient's current daily protein intake using a 24-hour diet recall. Set a protein target of 1.2 g per kg of current body weight per day and provide specific food-source guidance. Address iron if ferritin is below 30 ng/mL using alternate-day ferrous sulfate. Reassess at 8 to 12 weeks with repeat ferritin and clinical hair examination. Consider dose escalation pause if shedding is severe and nutritional correction has not produced improvement at 8 weeks. Refer to dermatology if the pattern is atypical or if shedding persists beyond 6 months.

According to the American Academy of Dermatology's clinical resource on hair loss evaluation, "Telogen effluvium is the most common cause of diffuse hair loss and is almost always reversible once the underlying trigger is identified and corrected." [14] That principle applies directly to the GLP-1 population.